The Claim

BPC 157 has not been established as a safe and effective medicinal product, as the only registered clinical trial (Phase I study NCT02637284) was cancelled, and available clinical safety data consists solely of small, unpublished studies with serious methodological limitations.

Source: Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on “Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals 2025, 18, 185”

What the research says

Not yet evaluated

We are still looking at what the research says.

Supports
0score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
0 studies reviewed
In plain English

There's only been one official clinical trial testing BPC 157 in humans, and it was cancelled. The other safety data we have comes from tiny, unpublished studies that aren't reliable enough to prove this peptide is safe or works as a medicine.

See the scientific wording

The only registered clinical trial of BPC 157 (Phase I study NCT02637284) was cancelled, and available clinical safety data consists of small, unpublished studies with serious methodological limitations that do not establish BPC 157 as a safe and effective medicinal product.

Score breakdown, mechanism chain, raw evidence, ideal studies needed

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.